Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma.
Saved in:
| Title: | Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. |
|---|---|
| Authors: | O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA rhv@upenn.edu oreillye@mskcc.org., Cabanski CR; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Lyman JP; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Wainberg ZA; University of California Los Angeles, Los Angeles, California, USA., Fisher GA; Department of Medicine, Stanford University School of Medicine, Stanford, California, USA., Wolff RA; MD Anderson Gastrointestinal Cancer Center, Houston, Texas, USA., Ko AH; Medicine (Division of Hematology/Oncology), University of California San Francisco, San Francisco, California, USA., O'Hara MH; Medicine, Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Spencer CN; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Yu JX; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Da Silva DM; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Padrón LJ; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Arnott J; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Fairchild J; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Moore JS; Abramson Cancer Center, Philadelphia, Pennsylvania, USA., Peng B; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Hoos WA; 1440 Foundation, Scotts Valley, California, USA., O'Donnell-Tormey J; Cancer Research Institute, New York, New York, USA., Boffo S; Bristol Myers Squibb, Princeton, New Jersey, USA., Dugan U; Parker Institute for Cancer Immunotherapy, San Francisco, California, USA., Kimmelman AC; NYU Langone Health Perlmutter Cancer Center, New York, New York, USA., Amaravadi RK; University of Pennsylvania, Philadelphia, Pennsylvania, USA., Vonderheide RH; Abramson Cancer Center, Philadelphia, Pennsylvania, USA rhv@upenn.edu oreillye@mskcc.org.; Parker Institute for Cancer Immunotherapy, Philadelphia, Pennsylvania, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Jan 30; Vol. 14 (1). Date of Electronic Publication: 2026 Jan 30. |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
